Skip to main content
SpringerLink
Log in

Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Data availability

Anonymized data not published within this article will be made available by request from qualified investigators.

References

  1. Nakayama M et al (2021) A review of clinical and imaging findings in tumefactive demyelination. AJR Am J Roentgenol 217(1):186–197

    Article  PubMed  Google Scholar 

  2. Hardy TA, Chataway J (2013) Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry 84(9):1047–1053

    Article  PubMed  Google Scholar 

  3. Clarke L et al (2021) Magnetic resonance imaging in neuromyelitis optica spectrum disorder. Clin Exp Immunol 206(3):251–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cacciaguerra L et al (2023) Tumefactive demyelination in MOG Ab-associated disease, multiple sclerosis, and AQP-4-IgG-positive neuromyelitis optica spectrum disorder. Neurology 100(13):e1418–e1432

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Seewann A et al (2008) MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings. J Neurol 255(1):1–10

    Article  CAS  PubMed  Google Scholar 

  6. Lucchinetti CF et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131(Pt 7):1759–1775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Suh CH et al (2018) MRI findings in tumefactive demyelinating lesions: a systematic review and meta-analysis. AJNR Am J Neuroradiol 39(9):1643–1649

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ikeguchi R et al (2018) Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas. Mult Scler Relat Disord 26:77–84

    Article  PubMed  Google Scholar 

  9. Fereidan-Esfahani M et al (2022) Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. Eur J Neurol 29(3):782–789

    Article  PubMed  Google Scholar 

  10. Cacciaguerra L et al (2019) Brain and cord imaging features in neuromyelitis optica spectrum disorders. Ann Neurol 85(3):371–384

    Article  PubMed  Google Scholar 

  11. Deisenhammer F et al (2019) The cerebrospinal fluid in multiple sclerosis. Front Immunol 10:726

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Di Gregorio M et al (2021) Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study. Eur J Neurol 28(4):1299–1307

    Article  PubMed  Google Scholar 

  13. Carta S et al (2022) Oligoclonal bands: clinical utility and interpretation cues. Crit Rev Clin Lab Sci 59(6):391–404

    Article  CAS  PubMed  Google Scholar 

  14. Wallner-Blazek M et al (2013) Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol 260(8):2016–2022

    Article  CAS  PubMed  Google Scholar 

  15. Hyland M, Bermel RA, Cohen JA (2013) Restricted diffusion preceding gadolinium enhancement in large or tumefactive demyelinating lesions. Neurol Clin Pract 3(1):15–21

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The study received no funding.

Author information

Authors and Affiliations

  1. Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Matteo Azzimonti, Monica Margoni, Federica Genovese, Maria A. Rocca & Massimo Filippi

  2. Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Matteo Azzimonti, Chiara Zanetta, Federica Genovese, Vittorio Martinelli, Maria A. Rocca, Lucia Moiola & Massimo Filippi

  3. Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Monica Margoni, Chiara Zanetta & Massimo Filippi

  4. Vita-Salute San Raffaele University, Milan, Italy

    Maria A. Rocca & Massimo Filippi

  5. Neuroradiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Cristina Baldoli

  6. Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Massimo Filippi

Authors
  1. Matteo Azzimonti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Margoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Zanetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Federica Genovese
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vittorio Martinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria A. Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cristina Baldoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lucia Moiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Massimo Filippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Filippi.

Ethics declarations

Conflicts of interest

M. Azzimonti received travel grants from Novartis. M. Margoni reports grants and personal fees from Almiral. She was awarded a MAGNIMS-ECTRIMS fellowship in 2020. C. Zanetta received compensation for speaking activities, and/or consulting services from Alexion, Biogen, Merck, Novartis, Roche, Sanofi. F. Genovese has nothing to disclose. V. Martinelli received compensation for speaking and/or for consultancy and support for travel expenses and participation in Congresses from Biogen, Merck-Serono, Novartis, Genzyme and TEVA Pharmaceutical Industries. M.A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders.. C. Baldoli has nothing to disclose. L. Moiola received compensation for speaking activities, and/or consulting servicesfrom Merck, Biogen, Novartis, Roche, Sanofi, and TEVA. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

Ethical approval

The Ethics Committee of San Raffaele Scientific Institute waived the need for ethics approval for publication of case reports.

Consent to participate

Written informed consent was obtained from patients for the usage of clinical data in anonymized fashion.

Consent for publication

Written informed consent was obtained from patients to publish their anonymized data and clinical history.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Azzimonti, M., Margoni, M., Zanetta, C. et al. Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis. J Neurol 271, 1663–1667 (2024). https://doi.org/10.1007/s00415-023-12164-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-023-12164-5

Search

Navigation